Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

AVDL holding history

Avadel Pharmaceuticals PLC in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AVDL overviewAll 13F holders of AVDLFull Q2 2026 holdings

Shares (Q1 2026)
0
Sold out in Q1 2026
Value
$0
% of portfolio
0.0%
Quarters held
20
Since Q1 2021
Holdings of AVDL by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20260$00.0%−344,933−100.0%Sold outHolders
Q4 2025344,933$7.43M<0.1%−333,048−49.1%ReducedHolders
Q3 2025677,981$10.4M<0.1%−197,258−22.5%ReducedHolders
Q2 2025875,239$7.75M<0.1%−419,393−32.4%ReducedHolders
Q1 20251,294,632$10.1M<0.1%−276,228−17.6%ReducedHolders
Q4 20241,570,860$16.5M<0.1%+963,556+158.7%AddedHolders
Q3 2024607,304$7.96M<0.1%+372,962+159.2%AddedHolders
Q2 2024234,342$3.29M<0.1%+220,812+1,632.0%AddedHolders
Q1 202413,530$228.5K<0.1%+2,230+19.7%AddedHolders
Q4 202311,300$159.6K<0.1%−134−1.2%ReducedHolders
Q3 202311,434$117.8K<0.1%−1,954−14.6%ReducedHolders
Q2 202313,388$220.6K<0.1%+2,717+25.5%AddedHolders
Q1 202310,671$97.7K<0.1%+7,745+264.7%AddedHolders
Q4 20222,926$20.9K<0.1%−9,029−75.5%ReducedHolders
Q3 202211,955$60.0K<0.1%+8,971+300.6%AddedHolders
Q2 20222,984$7.00K<0.1%−323−9.8%ReducedHolders
Q1 20223,307$23.0K<0.1%−4,951−60.0%ReducedHolders
Q4 20218,258$67.0K<0.1%−4,243−33.9%ReducedHolders
Q3 202112,501$122.0K<0.1%−983−7.3%ReducedHolders
Q2 202113,484$91.0K<0.1%+6,616+96.3%AddedHolders
Q1 20216,868$63.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.